| 2024-03-11 |
详情>>
内部人交易：
Lanza Frank J等共交易10笔
|
| 2024-03-09 |
复牌提示：
2024-03-08 19:50:00 停牌，复牌日期 2024-03-12 00:00:01
|
| 2024-02-08 |
股东大会：
将于2024-03-08召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to adopt the Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”), dated as of January 7, 2024, by and among Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Merck”), Hawaii Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Merck (“Merger Sub”), and Harpoon, pursuant to which Merger Sub will be merged with and into Harpoon, with Harpoon surviving as a wholly owned subsidiary of Merck (the “Merger”);
2.To consider and vote on a proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes in person or by proxy to approve the proposal to adopt the Merger Agreement at the time of the Special Meeting.
|
| 2024-02-08 |
详情>>
股本变动：
变动后总股本2139.72万股
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.17美元,归母净利润-1207.9万美元,同比去年增长75.50%
|
| 2023-09-05 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-0.28美元,归母净利润-1027.7万美元,同比去年增长72.72%
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-0.31美元,归母净利润-1133.8万美元,同比去年增长44.21%
|
| 2023-04-27 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees named in the attached Proxy Statement as directors to serve on the Board of Directors for a three-year term.
2.To approve an amendment to our amended and restated certificate of incorporation (the “Certificate of Incorporation”) to effect a reverse stock split of our issued and outstanding common stock at a ratio of 1-for-2 to 1-for-10, to be determined in the sole discretion of the Board of Directors.
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
4.To conduct any other business properly brought before the meeting or any adjournment or postponement thereof.
|
| 2023-03-27 |
详情>>
业绩披露：
2020年年报每股收益-1.99美元,归母净利润-4990.8万美元,同比去年增长10.19%
|
| 2023-03-27 |
详情>>
业绩披露：
2022年年报每股收益-2.04美元,归母净利润-6773.1万美元,同比去年增长41.97%
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.49美元,归母净利润-4931.2万美元,同比去年增长48.18%
|
| 2022-08-10 |
详情>>
业绩披露：
2022年中报每股收益-1.14美元,归母净利润-3767.2万美元,同比去年增长52.00%
|
| 2022-08-10 |
详情>>
业绩披露：
2021年中报每股收益-2.45美元,归母净利润-7848.7万美元,同比去年增长-210.91%
|
| 2022-05-12 |
详情>>
业绩披露：
2022年一季报每股收益-0.62美元,归母净利润-2032.1万美元,同比去年增长67.08%
|
| 2022-04-29 |
股东大会：
将于2022-06-22召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees named in the attached Proxy Statement as directors to serve on the Board of Directors for a three-year term.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To conduct any other business properly brought before the meeting or any adjournment or postponement thereof.
|
| 2022-03-10 |
详情>>
业绩披露：
2021年年报每股收益-3.62美元,归母净利润-1.17亿美元,同比去年增长-133.87%
|
| 2021-11-10 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-2.96美元,归母净利润-9516.9万美元,同比去年增长-146.87%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-24 |
股东大会：
将于2021-05-04召开股东大会
会议内容 ▼▲
- 1.To elect the three nominees named in the attached proxy statement as directors to serve on the Board of Directors for a three-year term.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To conduct any other business properly brought before the meeting or any adjournment or postponement thereof.
|
| 2021-03-10 |
财报披露：
美东时间 2021-03-10 盘后发布财报
|
| 2020-04-17 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.To elect the three nominees named in the attached proxy statement as directors to serve on the Board of Directors for a three-year term.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
3.To conduct any other business properly brought before the meeting or any adjournment or postponement thereof.
|